NEWS

Advancements in Patient-Centered Care

Stay up to date with the latest advancements in oral oncolytics, medically-integrated oncology, and cancer care best practices.

Chronic Lymphocytic Leukemia with Del17p

April 11, 2017

Written by Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates Download Here Description: Chronic Lymphocytic Leukemia (CLL) diagnosis with the chromosomal abnormality of 17p Deletion is associated with a poor prognosis.  The 17p deletion is found 3‐10% of the time at diagnosis, but 30‐ 50% at relapse.   Testing rates at diagnosis and especially relapse are low.  Venetoclax is […]
read more

DIRs: PBMs Pay Less Each Year While Prices Go Up

March 20, 2017

David Stanley recently contributed in the Modern Medicine Networking on how, "PBMs Pay Less Each Year While Prices Go Up". "Most of you are familiar with Medicare Part D direct and indirect remuneration (DIR) fees and know them as just another headache that comes along with your PBM contract. In a nutshell, when a DIR […]
read more

Update Patient Survey (English & Spanish)

March 15, 2017

NCODA has uploaded the updated patient survey in both English and Spanish in the member portal. Click here for English version. Click here for Spanish version.
read more

NCODA Spring Forum Agenda

February 22, 2017

This year’s Spring Summit in Chicago on March 2nd – 4th will cover a variety of topics such as: Sharing Value: NCODA Activities, Tools, Goals, ResourcesDefining EffectivenessAudits – Let’s hear from the auditorsIOD Accounting – Making Sense of the CentsMACRA/MIPS – What it means to you! Sybil GreenThe Problems with SPs and PBMs! War stories […]
read more

Implementing Oral Oncolytics: Steps to Success

November 30, 2016

As the use of oral oncolytics increases, cancer programs face a number of challenges to ensure high-quality care for cancer patients. There are significant variations in how cancer programs are treating patients with oral oncolytics. Arizona Oncology, a founding member of NCODA, is highlighted within:
read more

Big victory for Oncology Patients! – CVS pulls back on closing out in office dispensing.

October 31, 2016

Syracuse, NY, October 31, 2016 – NCODA (National Community Oncology Dispensing Association, Inc.) would like to highlight a major victory in the treatment landscape for oncology patients. On Thursday, October 27, CVS Health announced it had reversed its decision to limit Medicare Part D access away from oncology practices with in office dispensing as of […]
read more

PIF: Utah Cancer Specialists

June 1, 2016

MISSION STATEMENT/PHILOPSOPHY: The physicians, staff and management of Utah Cancer Specialists are dedicated to the diagnosis, treatment and management of all forms of cancer and blood related diseases. UCS is dedicated to helping people with these diseases achieve optimum health and quality of life through excellence in the delivery of compassionate medical care. UCS understands […]
read more

Practice in Focus: Virginia Cancer Specialist (VCS)

May 14, 2016

Mission Statement: Meeting and exceeding the needs of our patients is our primary goal. We recognize that each patient is an individual with unique needs. Our staff is dedicated to the fight against cancer and providing A New Way of Caring. Locations: Virginia Cancer Specialists has locations in Fairfax, Alexandria, Arlington, Fair Oaks, Gainesville, Loudon, […]
read more

NCODA Payor Update!

May 11, 2016

NCODA practices have successfully collaborated with another regional payor for the ability to go beyond the first fill! That brings the number of payers that have now collaborated with NCODA practices up to four! Several NCODA practices are currently in payor discussions!
read more

Waste in Cancer Drugs Costs $3 Billion a Year, a Study Says

May 11, 2016

WASHINGTON — The federal Medicare program and private health insurers waste nearly $3 billion every year buying cancer medicines that are thrown out because many drug makers distribute the drugs only in vials that hold too much for most patients, a group of cancer researchers has found. Click here for the New York Times Article… […]
read more

ONS:Edge White Paper: How to Overcome Adherence Challenges in Patients Taking Oral Therapy for mCRC

March 3, 2016

Oral oncolytic regimens have many benefits; however, patients can encounter barriers (e.g., institutional, socioeconomic, treatment) that can hinder their ability to take their medication as prescribed. Patients with metastatic colorectal cancer (mCRC) face complex dosing schedules that challenge adherence. When patients take oral therapies at home, healthcare professionals (HCPs) can use tools to empower their […]
read more

Antiemesis Prophylaxis Remains Inadequate

March 2, 2016

Approximately 40% of patients treated with anthracyclines are still not receiving National Comprehensive Cancer Network (NCCN) guideline–adherent prophylaxis for chemotherapy-induced vomiting. In most cases, guideline nonadherence was secondary to the lack of a neurokinin 1 (NK1) antagonist. Patients on highly emetogenic chemotherapy should receive prophylaxis in the form of a 5-HT3 antagonist in combination with […]
read more

RESOURCES

Cost Avoidance Waste Tracker

Positive Quality Interventions

PQI in Action

OCE Sheets

IVE Sheets

Treatment Support Kits

PQI Podcast

Members

Member Resources

OPTA

Committees

Member Login

Events

Webinars

Spring Forum

Oncology Institute

PSO Annual Meeting

Fall Summit

contact@ncoda.org

315-655-4640

P.O. Box 468
Cazenovia, NY 13035

NCODA is a 501(c)(3) Organization